JP2008099652A - Health food for metabolic syndrome - Google Patents
Health food for metabolic syndrome Download PDFInfo
- Publication number
- JP2008099652A JP2008099652A JP2006310757A JP2006310757A JP2008099652A JP 2008099652 A JP2008099652 A JP 2008099652A JP 2006310757 A JP2006310757 A JP 2006310757A JP 2006310757 A JP2006310757 A JP 2006310757A JP 2008099652 A JP2008099652 A JP 2008099652A
- Authority
- JP
- Japan
- Prior art keywords
- kotarahim
- mice
- health food
- metabolic syndrome
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013402 health food Nutrition 0.000 title claims abstract description 11
- 208000001145 Metabolic Syndrome Diseases 0.000 title claims abstract description 7
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title claims abstract description 7
- 239000000843 powder Substances 0.000 claims abstract description 8
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 239000010419 fine particle Substances 0.000 claims description 2
- 210000001596 intra-abdominal fat Anatomy 0.000 abstract description 10
- 241000196324 Embryophyta Species 0.000 abstract description 4
- 238000009825 accumulation Methods 0.000 abstract description 4
- 241000134253 Lanka Species 0.000 abstract description 3
- 241000647991 Salacia reticulata Species 0.000 abstract description 3
- 230000000694 effects Effects 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract 1
- 230000002724 inhibitory effect on hypertension Effects 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 29
- 230000036772 blood pressure Effects 0.000 description 10
- 210000004003 subcutaneous fat Anatomy 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000037396 body weight Effects 0.000 description 6
- 238000009395 breeding Methods 0.000 description 5
- 230000001488 breeding effect Effects 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000003925 fat Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000545263 Salacia <hydroid> Species 0.000 description 2
- 206010049040 Weight fluctuation Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003276 anti-hypertensive effect Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000036760 body temperature Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- OMKXVFDVAGCPBS-GTEYUELZSA-N [(2s,3s,4r,5r,6s)-1-[(2r,3s,4s)-3,4-dihydroxy-2-(hydroxymethyl)thiolan-1-ium-1-yl]-2,4,5,6,7-pentahydroxyheptan-3-yl] sulfate Chemical compound OC[C@H](O)[C@@H](O)[C@@H](O)[C@H](OS([O-])(=O)=O)[C@H](O)C[S+]1C[C@@H](O)[C@H](O)[C@H]1CO OMKXVFDVAGCPBS-GTEYUELZSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
本発明は、メタボリックシンドローム用健康食品に関するものである。 The present invention relates to a health food for metabolic syndrome.
メタボリックシンドロームは、最近の重要課題として取り上げられているが、これは、内臓脂肪の蓄積を基盤とした食後高血糖・血清脂質代謝異常・高血圧を呈する症候群であって、長期病態を持続することにより動脈硬化や心疾患系症状を呈して、死に至るおそれがあるものである。メタボリックシンドロームに対する治療薬は、現状では未だ少なく、予防薬や治療薬の開発が望まれている。 Metabolic syndrome has been taken up as an important issue recently, but it is a syndrome of postprandial hyperglycemia, serum lipid metabolism abnormalities, and hypertension based on the accumulation of visceral fat. It presents arteriosclerosis and heart disease symptoms and can lead to death. Currently, there are still few therapeutic drugs for metabolic syndrome, and development of preventive drugs and therapeutic drugs is desired.
一方、コタラヒンブツ(kothala himubutu.salacia reticulata)は、スリランカ民主社会主義共和国にのみ自生する多年生蔓性木本で、デチンムル科またはニシキギ科に分類されている。この植物の木部を粉砕した粉末やそれを煎じた抽出液が血糖降下に有効であることは現地では古くから知られていたが、その他の薬効について不明であった(非特許文献1参照)。 On the other hand, Kotala Himubutu (Salacia reticulata) is a perennial vine that grows only in the Democratic Socialist Republic of Sri Lanka, and is classified into the Dechinmuraceae or the Physiaceae family. Although it has long been known locally that the powder obtained by pulverizing the xylem of this plant and the extract decocted thereof are effective in lowering blood sugar, other medicinal effects were unclear (see Non-Patent Document 1). .
コタラヒンブツは、サラシノール(Salasinol)やコタラノール(Kotalanol)などの各種の有効成分を含有することが知られてきているが、未だ詳細な研究がなされておらず、一層の研究がなされる必要がある。 Kotara Hinbutu has been known to contain various active ingredients such as Sarasinol and Kotalanol, but has not been studied in detail yet, and further research needs to be conducted.
本発明は、内臓脂肪の蓄積を未然に回避することができるのみならず、高血圧の抑制効果も優れており、健康食品として副作用なく長期間にわたって使用するには好適であるメタボリックシンドローム用健康食品を提供するものである。 The present invention not only prevents the accumulation of visceral fat, but also has an excellent antihypertensive effect and is suitable for use over a long period of time without side effects as a health food. It is to provide.
本発明は、上記目的を達成するものであって、請求項1記載の発明は、コタラヒンブツを微粒子状に粉砕した粉末又はコタラヒンブツの抽出物を含有していることを特徴とするコタラヒンブツを含有する健康食品である。 The present invention achieves the above-mentioned object, and the invention according to claim 1 contains a powder obtained by pulverizing Kotara Hinbuts into a fine particle or an extract of Kotara Hinbuts, which is a health containing Kotara Hinbuts It is food.
本発明は、コタラヒンブツに含有される各種の有効成分を効率良く使用することにより、コタラヒンブツの各種の有効成分を有効に含有する健康食品を提供することができるものであって、本発明によって得られるコタラヒンブツの有効成分は、内臓脂肪の蓄積を未然に回避することができるのみならず、高血圧の抑制効果も優れており、健康食品として副作用なく長期間にわたって使用するには好適である。 The present invention can provide a health food that effectively contains various active ingredients of Kotara Hinbutu by efficiently using the various active ingredients contained in Kotara Hinbutu, and is obtained by the present invention. The active ingredient of Kotara Hinbutsu not only can avoid the accumulation of visceral fat, but also has an excellent antihypertensive effect and is suitable for use as a health food for a long period without side effects.
本発明で使用するコタラヒンブツは、スリランカ民主社会主義共和国の特産のつる性植物であって、乾燥状態のものを使用することが望ましいが、これに限らない。乾燥状態の程度は、水分率10%以下に設定することが望ましい。水分率10%より多量の水分率を有するコタヒンブツを乾燥することが望ましい。 Kotara Hinbutsu used in the present invention is a special vine plant of the Democratic Socialist Republic of Sri Lanka, and it is desirable to use a dried plant, but it is not limited to this. It is desirable to set the degree of dryness to a moisture content of 10% or less. It is desirable to dry Kota Hinbutu having a moisture content greater than 10%.
先ず、コタラヒンブツの木部や葉部を粉砕するが、この粉砕処理はジェットミル(ジェット粉砕機)などを使用して粉砕することが望ましいが、これに限らない。 First, the wood part and leaf part of Kotara Hinbuts are pulverized, but this pulverization is preferably performed using a jet mill (jet pulverizer) or the like, but is not limited thereto.
コンタラヒムブツの使用に際しては、粉砕物を熱水で抽出することが望ましいが、コタラヒンブツ粉砕物の重量に対して10〜1000倍程度の水を使用することが望ましいが、これに限らない。熱水の温度は80℃以上100℃以下の温度範囲内が望ましいが、加圧下で高温を採用することも可能である。なお、上記抽出にはアルコール類其の他の有機溶剤の使用も可能である。 When using Kontala Himubutu, it is desirable to extract the pulverized product with hot water, but it is desirable to use about 10 to 1000 times as much water as the weight of Kotara Hinbutsu pulverized product, but this is not restrictive. The temperature of the hot water is preferably in the temperature range of 80 ° C. or more and 100 ° C. or less, but it is possible to employ a high temperature under pressure. For the extraction, alcohols and other organic solvents can be used.
さらに、本発明のコタラヒンブツの粉末又は抽出物は、食品への添加物として使用されるが、健康食品に使用する食品としては、パン類、ご飯類、めん類、菓子類、水産加工品、乳製品、飲料、調味料、食品補助品などであって、これらに本発明のコタラヒンブツの粉末又は抽出物を混合して健康食品とすることができる。なお、本発明のコタラヒンブツの粉末は、直接飲料として使用することも可能であり、この場合には、粉砕物を熱水で抽出することが望ましいが、コタラヒンブツ粉砕物の重量に対して10〜1000倍程度の水を使用することが望ましいが、これに限らない。 Further, the powder or extract of Kotara Hinbutu of the present invention is used as an additive to foods, but as foods used for health foods, breads, rices, noodles, confectionery, processed marine products, dairy products These are beverages, seasonings, food supplements, etc., which can be mixed with the powder or extract of Kotara Hinbutu of the present invention to make a health food. The powder of Kotara Hinbuts of the present invention can also be used directly as a beverage. In this case, it is desirable to extract the pulverized product with hot water. Although it is desirable to use about twice as much water, it is not limited to this.
実施例1
コタラヒンブツの木部を粉砕して得られた微粉末を水に浸し、80℃に加熱し、2時間保持して抽出処理をした。冷却し、濾過によって固形分を除去して熱水抽出液を得た。得られた熱水抽出液を乾燥し、等量のシクロデキストリンを添加して粉末化して、本研究用のコタラヒムを得た。Example 1
The fine powder obtained by pulverizing the wood part of Kotara Hinbutu was soaked in water, heated to 80 ° C. and held for 2 hours for extraction treatment. After cooling, the solid content was removed by filtration to obtain a hot water extract. The obtained hot water extract was dried and powdered by adding an equal amount of cyclodextrin to obtain Kotarahim for this study.
実験動物としては、自然発症2型糖尿病肥満モデルマウスであるTSOD(Tsumura,Suzuki,Obese,Diabetes)マウス24匹を用いた。これらのマウスは、3週齢のTSOD系雄性マウスであって、財団法人動物繁殖研究所(茨城県)より入手したものである。マウスは、室温23±2℃、湿度55±10%、1日12時間の昼夜サイクル下の飼育室で飼育し、粉末飼料MF(オリエンタル酵母株式会社)と水を自由に与え、1週間の予備飼育をした後に4週齢時より下記の本研究飼育に切り換えた。 Twenty-four TSOD (Tsumura, Suzuki, Obese, Diabetes) mice, which are spontaneous type 2 diabetes obesity model mice, were used as experimental animals. These mice are 3-week-old male TSOD mice and were obtained from the Institute for Animal Breeding (Ibaraki Prefecture). Mice are raised in a breeding room under a day / night cycle of room temperature 23 ± 2 ° C, humidity 55 ± 10%, 12 hours a day, and freely given powdered diet MF (Oriental Yeast Co., Ltd.) and water for 1 week. After breeding, the animals were switched to the following research breeding from the age of 4 weeks.
上記のマウス24匹を対照群、コタラヒム1%使用群(コタラヒム低用量群)、コタラヒム3%使用群(コタラヒム高用量群)の3群に各8匹ずつに群分けし、対照群には粉末飼料MFのみを、コタラヒム1%使用群には粉末飼料MFと1.0%のコタラヒム混餌飼料を、コタラヒム3%使用群には粉末飼料MFと3.0%のコタラヒム混餌飼料を、それぞれ自由摂取させ、12週齢時までの8週間にわたって飼育した。 The 24 mice described above were divided into 3 groups of control group, Kotarahim 1% use group (Kotarahim low dose group), Kotarahim 3% use group (Kotarahim high dose group), 8 mice each, Only feed MF, powdered MF and 1.0% Kotarahim mixed feed for the Kotarahim 1% use group, powdered feed MF and 3.0% Kotarahim mixed feed for the Kotarahim 3% use group, respectively And raised for 8 weeks until 12 weeks of age.
上記の本研究飼育開始時及び飼育中において、対照群、コタラヒム1%使用群、コタラヒム3%使用群の3群のマウスについて、体重変化、摂餌量、内臓脂肪量、皮下脂肪量、血圧などを測定して、対比した。 Changes in body weight, food intake, visceral fat mass, subcutaneous fat mass, blood pressure, etc. for the mice in the control group, the 1% use group of Kotarahim, and the 3% use group of Kotarahim at the start of this study Were measured and compared.
体重変化について
体重は、実験開始時(0週)より終了時(8週)まで、1週間毎に測定した。About change in body weight The body weight was measured every week from the start of the experiment (week 0) to the end of the experiment (week 8).
1.対照群のマウスの体重変動は下記のとおりであった。
2.コタラヒム1%使用群のマウスの体重変動は下記のとおりであった。
3.コタラヒム3%使用群のマウスの体重変動は下記のとおりであった。
1. The change in body weight of the mice in the control group was as follows.
2. The weight fluctuations of the mice in the 1% use group of Kotarahim were as follows.
3. The body weight fluctuations of the mice in the Kotarahim 3% use group were as follows.
対照群、コタラヒム1%使用群、コタラヒム3%使用群の3群のマウスについて、体重変化を対比したところ、コタラヒムを添加しない飼料で飼育したマウスは体重増加が大きく、肥満状態となったが、コタラヒム1%使用群、コタラヒム3%使用群のマウスは体重増加が少なく、肥満状態となるのを防止することができた。 The mice in the control group, the 3% use group of Kotarahim, and the 3% use group of Kotarahim, compared the changes in body weight. As a result, the mice bred with a diet not containing Kotarahim had a large weight gain and became obese. The mice in the Kotarahim 1% use group and Kotarahim 3% use group had little weight gain and were able to prevent becoming obese.
内臓脂肪量および皮下脂肪量の変化について
実験開始時(0週)、4週、実験終了時(8週)において、マウスをネンブタール麻酔(50mg/kg,i.p.)下で実験動物用X線CT装置La Theta(株式会社アロカ)にセットし、剣状突起から仙骨まで1.5mm間隔でスキャンして内臓脂肪重量および皮下脂肪重量を測定した。Changes in Visceral Fat Volume and Subcutaneous Fat Volume At the start of the experiment (week 0), 4 weeks, and at the end of the experiment (week 8), the mice were subjected to laboratory animal X under Nembutal anesthesia (50 mg / kg, ip). Visceral fat weight and subcutaneous fat weight were measured by setting the line CT apparatus La Theta (Aloka Co., Ltd.) and scanning from the xiphoid process to the sacrum at 1.5 mm intervals.
1.対照群のマウスの内蔵脂肪は下記のとおりであった。
2.コタラヒム1%使用群のマウスの内蔵脂肪は下記のとおりであった。
3.コタラヒム3%使用群のマウスの内蔵脂肪は下記のとおりであった。
1. The internal fats of the mice in the control group were as follows.
2. The internal fats of mice in the 1% use group of Kotarahim were as follows.
3. The internal fats of mice in the Kotarahim 3% use group were as follows.
1.対照群のマウスの皮下脂肪は下記のとおりであった。
2.コタラヒム1%使用群のマウスの皮下脂肪は下記のとおりであった。
3.コタラヒム3%使用群のマウスの皮下脂肪は下記のとおりであった。
1. The subcutaneous fat of the control group of mice was as follows.
2. The subcutaneous fat of mice in the Kotarahim 1% use group was as follows.
3. The subcutaneous fat of mice in the Kotarahim 3% use group was as follows.
対照群、コタラヒム1%使用群、コタラヒム3%使用群の3群のマウスについて、内臓脂肪及び皮下脂肪を対比したところ、コタラヒムを添加しない飼料で飼育したマウスは内臓脂肪及び皮下脂肪が顕著に増加したが、コタラヒム1%使用群、コタラヒム3%使用群のマウスは内臓脂肪及び皮下脂肪がほとんど増加しなかった。 When the visceral fat and subcutaneous fat were compared in the mice of the control group, the 1% using Kotarahim group, and the 3% using Kotarahim group, the visceral fat and subcutaneous fat were significantly increased in the mice fed with the diet not containing Kotarahim. However, the visceral fat and the subcutaneous fat were hardly increased in the mice in the Kotarahim 1% use group and the Kotarahim 3% use group.
血圧について
本研究飼育後の各マウスを保定器THC−2(((株)Softron、東京)に保定し37℃に体温を保ちながら、尾を基部まで非観血式血圧測定器BP−98A((株)Softron、東京)のtail cuffに差し込み非観血で血圧を測定した。収縮期血圧、拡張期血圧、平均血圧についての測定結果を示す。About blood pressure Each mouse after breeding in this study was held in a holding device THC-2 (Softron, Tokyo, Japan) and maintained the body temperature at 37 ° C., while maintaining the body temperature at 37 ° C., a non-invasive blood pressure measuring device BP-98A ( Blood pressure was measured by non-invasive blood pressure insertion into tail cuff of Softtron Co., Ltd. Measurement results of systolic blood pressure, diastolic blood pressure, and average blood pressure are shown.
1.対照群のマウスの各血圧は下記のとおりであった。
2.コタラヒム1%使用群のマウスの各血圧は下記のとおりであった。
3.コタラヒム3%使用群のマウスの各血圧は下記のとおりであった。
1. Each blood pressure of the control group mice was as follows.
2. Each blood pressure of the mice in the 1% use group of Kotarahim was as follows.
3. Each blood pressure of the mice in the Kotarahim 3% use group was as follows.
本研究飼育後の対照群、コタラヒム1%使用群、コタラヒム3%使用群の3群のマウスについて、血圧を対比したところ、コタラヒムを添加しない飼料で飼育したマウスは血圧が高く、高血圧状態であったが、コタラヒム1%使用群、コタラヒム3%使用群のマウスは血圧が高くなく、健康状態であった。 After comparing the blood pressure of the three groups of mice, the control group, the 1% use group of Kotarahim, and the 3% use group of Kotarahim after breeding in this study, the mice raised on the diet without the addition of Kotarahim had high blood pressure and were in a hypertensive state. However, the mice in the Kotarahim 1% use group and the Kotarahim 3% use group did not have high blood pressure and were in a healthy state.
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006310757A JP2008099652A (en) | 2006-10-20 | 2006-10-20 | Health food for metabolic syndrome |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006310757A JP2008099652A (en) | 2006-10-20 | 2006-10-20 | Health food for metabolic syndrome |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2008099652A true JP2008099652A (en) | 2008-05-01 |
Family
ID=39434489
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006310757A Pending JP2008099652A (en) | 2006-10-20 | 2006-10-20 | Health food for metabolic syndrome |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2008099652A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009093755A1 (en) * | 2008-01-23 | 2009-07-30 | Fujifilm Corporation | Agent for increasing blood adiponectin quantity |
JP2009179579A (en) * | 2008-01-30 | 2009-08-13 | Seiko:Kk | Lipase inhibitor, and composition comprising the same |
JP2010011749A (en) * | 2008-07-01 | 2010-01-21 | Seiko:Kk | Noodle mixed with crushed product of leaf of salacia plant |
JP2010041962A (en) * | 2008-08-13 | 2010-02-25 | Seiko:Kk | Oil-and-fat processed food mixed with ground leaf of salacia plant |
JP2010235542A (en) * | 2009-03-31 | 2010-10-21 | Kobayashi Pharmaceutical Co Ltd | Muscle enhancer or basal metabolism enhancer |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001226275A (en) * | 2000-02-10 | 2001-08-21 | Shimizu Osamu | Glucose tolerance ameliorator |
JP2003012529A (en) * | 2001-06-26 | 2003-01-15 | Takama:Kk | Antidiabetic agent and diet agent |
JP2003063974A (en) * | 2001-08-27 | 2003-03-05 | Nippon Bio Kk | Antioxidant, nitrogen monooxide-production inhibitor, antiulcer drug and food containing the drug component |
WO2005030236A1 (en) * | 2003-09-26 | 2005-04-07 | Sky International Co. Ltd | Substance having intrahepatic glyconeogenesis inhibiting activity and food or food additive containing the substance |
JP2005323581A (en) * | 2004-04-13 | 2005-11-24 | Takashi Kondo | Health food containing salacia reticulata and method for producing the same |
JP2006042623A (en) * | 2004-07-30 | 2006-02-16 | Takashi Kondo | Bread and health food containing salacia reticulata |
JP2006160710A (en) * | 2004-12-10 | 2006-06-22 | Nippon Yakuyo Shokuhin Kenkyusho:Kk | Diabetes prevention and treatment composition and health food containing active ingredients thereof |
JP2006238811A (en) * | 2005-03-04 | 2006-09-14 | Amimoto Giken Kk | Brown rice-containing soybean curd and method for producing the same |
JP2006280236A (en) * | 2005-03-31 | 2006-10-19 | Amimoto Giken Kk | Food material brown rice, food produced using the brown rice, and food to which the brown rice is added |
-
2006
- 2006-10-20 JP JP2006310757A patent/JP2008099652A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001226275A (en) * | 2000-02-10 | 2001-08-21 | Shimizu Osamu | Glucose tolerance ameliorator |
JP2003012529A (en) * | 2001-06-26 | 2003-01-15 | Takama:Kk | Antidiabetic agent and diet agent |
JP2003063974A (en) * | 2001-08-27 | 2003-03-05 | Nippon Bio Kk | Antioxidant, nitrogen monooxide-production inhibitor, antiulcer drug and food containing the drug component |
WO2005030236A1 (en) * | 2003-09-26 | 2005-04-07 | Sky International Co. Ltd | Substance having intrahepatic glyconeogenesis inhibiting activity and food or food additive containing the substance |
JP2005323581A (en) * | 2004-04-13 | 2005-11-24 | Takashi Kondo | Health food containing salacia reticulata and method for producing the same |
JP2006042623A (en) * | 2004-07-30 | 2006-02-16 | Takashi Kondo | Bread and health food containing salacia reticulata |
JP2006160710A (en) * | 2004-12-10 | 2006-06-22 | Nippon Yakuyo Shokuhin Kenkyusho:Kk | Diabetes prevention and treatment composition and health food containing active ingredients thereof |
JP2006238811A (en) * | 2005-03-04 | 2006-09-14 | Amimoto Giken Kk | Brown rice-containing soybean curd and method for producing the same |
JP2006280236A (en) * | 2005-03-31 | 2006-10-19 | Amimoto Giken Kk | Food material brown rice, food produced using the brown rice, and food to which the brown rice is added |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009093755A1 (en) * | 2008-01-23 | 2009-07-30 | Fujifilm Corporation | Agent for increasing blood adiponectin quantity |
JP2009196981A (en) * | 2008-01-23 | 2009-09-03 | Fujifilm Corp | Agent for increasing blood adiponectin quantity |
JP2009179579A (en) * | 2008-01-30 | 2009-08-13 | Seiko:Kk | Lipase inhibitor, and composition comprising the same |
JP2010011749A (en) * | 2008-07-01 | 2010-01-21 | Seiko:Kk | Noodle mixed with crushed product of leaf of salacia plant |
JP2010041962A (en) * | 2008-08-13 | 2010-02-25 | Seiko:Kk | Oil-and-fat processed food mixed with ground leaf of salacia plant |
JP2010235542A (en) * | 2009-03-31 | 2010-10-21 | Kobayashi Pharmaceutical Co Ltd | Muscle enhancer or basal metabolism enhancer |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5334448B2 (en) | Glutathione production promoter and preventive / therapeutic agent for diseases caused by glutathione deficiency | |
JP2008099652A (en) | Health food for metabolic syndrome | |
JP6133471B2 (en) | Xanthine oxidase inhibitor | |
JP3671190B1 (en) | Extract obtained from lotus plant, method for producing the extract and anti-obesity agent | |
JP2011173847A (en) | Weight gain inhibitory composition and food containing the same | |
TW201034580A (en) | Agent for promoting weight gain in livestock, feed for promoting weight gain and method for promoting weight gain | |
JP3628999B2 (en) | Anonymous tea and its manufacturing method | |
JP5635765B2 (en) | Life-style related disease prevention or improvement agent | |
JP2007230987A (en) | Anti-obestic agent | |
KR20130083427A (en) | Composition for preventing, improving, or treating a disease controlled by ppar action | |
JP2011037811A (en) | Fat-decreasing composition | |
CN108208813A (en) | A kind of weight-reducing with health role disappears fat piece and preparation method thereof | |
WO2016046795A1 (en) | Protein dietary supplement | |
KR101337918B1 (en) | Ell bone use composition for improvement of cholesterol | |
JP6671367B2 (en) | Anti-obesity composition containing cyclic dipeptide | |
JP6786490B2 (en) | Anti-obesity composition | |
JP6857976B2 (en) | Growth hormone receptor expression improver and composition containing it | |
JP7253764B2 (en) | athletic performance enhancer | |
JP2013224286A (en) | Oral fat mass reducing agent, oral adiponectin production promoter, and lipid droplet accumulation inhibitor | |
JP4445145B2 (en) | Oral composition | |
TW202005663A (en) | Bitter gourd peptide composition and use thereof capable of reducing the rate of visceral fat increase and the rate of body fat formation | |
JP5565016B2 (en) | Composition for improving hypothermia and composition for improving cooling | |
JP2008115087A (en) | Hepatic function ameliorating agent | |
JP2006306840A (en) | Anti-obesity agent and food containing the anti-obesity agent | |
JP2017206477A (en) | Myogenesis promoting composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091016 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20110125 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110208 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111018 |